A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine theEffects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary BiliaryCholangitis (PBC) and an Incomplete Response or Intole

Project: Research project

Project Details

Description

A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intole
StatusActive
Effective start/end date4/30/24 → 4/30/34

Funding

  • CYMABAY THERAPEUTICS, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint